Pathos AI is paying $125M upfront for an Alphamab Oncology ADC that its Foundry agent platform flagged, plus a new…
Boehringer Ingelheim pays $15M for Immunai's AI platform to find shared T-cell targets across cancer and autoimmune disease.
The Series D funds targeted alpha therapy for solid tumors using AI-powered isotope targeting.
A deep learning model predicts aggressive liver cancer from CT scans across 3,100 patients, potentially replacing biopsies for treatment selection.
Owkin and AstraZeneca are expanding their AI collaboration to develop new drug discovery models using federated learning, a technique that…